John M - Search Results

1

Molecular mechanisms of HIV type 1 prophylaxis failure revealed by single-genome sequencing.

Li H, Blair L, Chen Y, Learn G, Pfafferott K, John M, Bhattacharya T, Hahn BH, Mallal S, Shaw GM, Bar KJ. Li H, et al. Among authors: john m. J Infect Dis. 2013 Nov 15;208(10):1598-603. doi: 10.1093/infdis/jit485. Epub 2013 Sep 9. J Infect Dis. 2013. PMID: 24023257 Free PMC article.

2

Highly active antiretroviral therapy.

French M, Lenzo N, John M, Mallal S, Price P. French M, et al. Among authors: john m. Lancet. 1998 Apr 4;351(9108):1056-7; author reply 1058-9. doi: 10.1016/S0140-6736(05)79021-8. Lancet. 1998. PMID: 9546530 No abstract available.

3

Antiretroviral therapy and the lipodystrophy syndrome.

John M, Nolan D, Mallal S. John M, et al. Antivir Ther. 2001 Mar;6(1):9-20. doi: 10.1177/135965350100600102. Antivir Ther. 2001. PMID: 11417766 Review.

4

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.

French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML. French MA, et al. Among authors: john m. HIV Med. 2000 Mar;1(2):107-15. doi: 10.1046/j.1468-1293.2000.00012.x. HIV Med. 2000. PMID: 11737333 Free article.

5

Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

Nolan D, John M, Mallal S. Nolan D, et al. Among authors: john m. Antivir Ther. 2001 Sep;6(3):145-60. Antivir Ther. 2001. PMID: 11808750 Review.

6

Hyperlactatemia syndromes in people with HIV infection.

John M, Mallal S. John M, et al. Curr Opin Infect Dis. 2002 Feb;15(1):23-9. doi: 10.1097/00001432-200202000-00005. Curr Opin Infect Dis. 2002. PMID: 11964902

7

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.

Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Moore CB, et al. Among authors: john m. Science. 2002 May 24;296(5572):1439-43. doi: 10.1126/science.1069660. Science. 2002. PMID: 12029127 Free article.

8

Viral load detectability profiles for HIV infection.

McKinnon EJ, James IR, John M, Mallal SA. McKinnon EJ, et al. Among authors: john m. Stat Med. 2003 Feb 15;22(3):385-96. doi: 10.1002/sim.1325. Stat Med. 2003. PMID: 12529870

9

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA. John M, et al. J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33. doi: 10.1097/00126334-200305010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12792352 Clinical Trial.

10

Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground.

Nolan D, Gaudieri S, John M, Mallal S. Nolan D, et al. Among authors: john m. AIDS. 2004 Jun 18;18(9):1231-40. doi: 10.1097/00002030-200406180-00001. AIDS. 2004. PMID: 15362655 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,183 results

Search Page

Filters